Stockscreener 앱 받기
0.855
9.79%
-0.0928
시간 외 거래:
.87
0.015
+1.75%
전일 마감가:
$0.9478
열려 있는:
$0.92
하루 거래량:
99,026
Relative Volume:
0.47
시가총액:
$66.06M
수익:
$3.91M
순이익/손실:
$-206.53M
주가수익비율:
-0.3444
EPS:
-2.4825
순현금흐름:
$-167.78M
1주 성능:
+5.49%
1개월 성능:
+25.74%
6개월 성능:
-24.34%
1년 성능:
-51.42%
1일 변동 폭
$0.8506
$0.9311
1주일 범위
$0.805
$0.965
52주 변동 폭
$0.595
$2.00
I Mab Adr Stock (IMAB) Company Profile
IMAB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMAB
I Mab Adr
|
0.855 | 66.06M | 3.91M | -206.53M | -167.78M | -2.4825 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
I Mab Adr Stock (IMAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-12-09 | 개시 | Siebert Williams Shank | Buy |
| 2021-06-02 | 개시 | Daiwa Securities | Buy |
| 2021-03-15 | 개시 | Needham | Buy |
| 2021-03-03 | 재확인 | H.C. Wainwright | Buy |
| 2021-02-25 | 개시 | Piper Sandler | Overweight |
| 2020-12-07 | 개시 | H.C. Wainwright | Buy |
| 2020-07-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-02-12 | 개시 | China Renaissance | Buy |
| 2020-02-11 | 개시 | Jefferies | Buy |
모두보기
I Mab Adr 주식(IMAB)의 최신 뉴스
After Plunging -20.33% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB) - Yahoo Finance
After Plunging -19.7% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB) - Yahoo Finance
I-Mab at Needham Conference: Strategic Transformation Unveiled - Investing.com
I-Mab at Needham Conference: Strategic Transformation Unveiled By Investing.com - Investing.com South Africa
I-Mab’s Transformative Year: Financial and Strategic Highlights - TipRanks
I-Mab stock price target lowered to $7 at H.C. Wainwright By Investing.com - Investing.com South Africa
I-Mab stock price target lowered to $7 at H.C. Wainwright - Investing.com India
I-Mab Reports Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire Inc.
I-Mab stock touches 52-week low at $0.72 amid market challenges - Investing.com
I-Mab faces Nasdaq delisting over bid price rule By Investing.com - Investing.com South Africa
I-Mab faces Nasdaq delisting over bid price rule - Investing.com
I-Mab advances gastric cancer treatment with swift trial enrollment - Investing.com
I-Mab stock touches 52-week low at $0.76 amid market challenges - Investing.com India
I-Mab ADR (IMAB) stock analysis: A simple moving average approach - US Post News
Use of failure mode and effect analysis to improve the monoclonal antibody drugs management process in pharmacy intravenous admixture services | Scientific Reports - Nature
I-Mab Chairman plans $2 million ADS purchase - Investing.com India
I-Mab’s Third Quarter Results: Progress in Cancer Immunotherapies - MSN
I-Mab names Sean Fu as new CEO - Investing.com India
Invitation: Vallourec Q3 2024 Results ReleaseConference Call on Friday, November 15, 2024 - The Manila Times
Would I Buy Spectral AI Inc (NASDAQ: MDAI) Stock At Any Time In The Future? - Stocks Register
Analyst Forecast For Grab Holdings Limited (NASDAQ: GRAB) - Stocks Register
IMab (IMAB) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
Piper Sandler cuts I-Mab stock target to $10, keeps overweight rating - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Minnelide combined with anti-ANGPTL3-FLD monoclonal antibody completely protects mice with adriamycin nephropathy by promoting autophagy and inhibiting apoptosis - Nature
I-Mab: Dropping Coverage - Morningstar
I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023 - Barchart.com
I-Mab Full-Year Update Uneventful; Potential Catalysts in H2 2023 - Morningstar
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022 - PR Newswire
Morningstar’s Best- and Worst-Performing Stocks: 2022 - Morningstar
Results for A amyloid PET SUVr and B Centiloid scale assessments from study 201 core - ResearchGate
The Cheapest Stock in the World - Morningstar.ca
10 of the Cheapest Stocks of 2022 - Morningstar
Why Are Some China Healthcare Stocks Up 50%? - HK.Morningstar.com
Fig. 3 A Scatchard analysis of 125 I-trastuzumab binding to human... - ResearchGate
Anti-ANGPTL3-FLD monoclonal antibody treatment ameliorates podocyte lesions through attenuating mitochondrial damage - Nature
The Best- and Worst-Performing Stocks: Q3 2022 - Morningstar
Markets Brief: Stocks Fall for the First Time in a Month, More Retail Earnings Ahead - Morningstar
Fig. 2 Flowchart of Sicilian adverse drug reaction (ADR) report... - ResearchGate
Markets Brief: How High Can Mortgage Rates Go? - Morningstar
New 5-Star Stocks - Morningstar
HFCAA News: 128 Chinese Stocks the SEC Could Delist - InvestorPlace
Safety Profile of Monoclonal Antibody Compared With Traditional Anticancer Drugs: An Analysis of Henan Province Spontaneous Reporting System Database - Frontiers
The Daily Biotech Pulse: AbbVie In-licenses I-Mab's Cancer Drug, Savara Pulls The Plug On Cystic Fibrosis Study - Yahoo Finance
I-MabADR to Host Earnings Call - AccessWire
Citi Appointed as Depositary Bank for I-Mab’s Sponsored ADR Program - Business Wire
Figure 1: Conventional antibody expression in E. coli. Most of the... - ResearchGate
Figure 2: Alternative antibody expression in E. coli cytoplasm.... - ResearchGate
Table 2 : The seven types of headache arising from abnormalities within... - ResearchGate
Notch2 activation ameliorates nephrosis - Nature
I Mab Adr (IMAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):